281 related articles for article (PubMed ID: 34235974)
1. TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases.
Gonciarz M; Pawlak-Buś K; Leszczyński P; Owczarek W
Immunotherapy; 2021 Sep; 13(13):1135-1150. PubMed ID: 34235974
[TBL] [Abstract][Full Text] [Related]
2. TYK2: an emerging therapeutic target in rheumatic disease.
Morand E; Merola JF; Tanaka Y; Gladman D; Fleischmann R
Nat Rev Rheumatol; 2024 Apr; 20(4):232-240. PubMed ID: 38467779
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory Diseases.
Muromoto R; Shimoda K; Oritani K; Matsuda T
Biol Pharm Bull; 2021; 44(11):1585-1592. PubMed ID: 34719635
[TBL] [Abstract][Full Text] [Related]
4. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
Roskoski R
Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
[TBL] [Abstract][Full Text] [Related]
5. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B
Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748
[TBL] [Abstract][Full Text] [Related]
6. Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise.
Danese S; Peyrin-Biroulet L
Inflamm Bowel Dis; 2021 Nov; 27(12):2023-2030. PubMed ID: 34089259
[TBL] [Abstract][Full Text] [Related]
7. Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019-2021).
Gonzalez Lopez de Turiso F; Guckian K
Expert Opin Ther Pat; 2022 Apr; 32(4):365-379. PubMed ID: 35001782
[TBL] [Abstract][Full Text] [Related]
8. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
[TBL] [Abstract][Full Text] [Related]
9. Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases.
Fang Z; Sun H; Wang Y; Sun Z; Yin M
Biomed Pharmacother; 2023 Nov; 167():115611. PubMed ID: 37778274
[TBL] [Abstract][Full Text] [Related]
10. Modifying T cell phenotypes using TYK2 inhibitor and its implications for the treatment of systemic lupus erythematosus.
Satoh-Kanda Y; Nakayamada S; Kubo S; Yamagata K; Nawata A; Tanaka H; Kosaka S; Kanda R; Yu S; Fujita Y; Sonomoto K; Tanaka Y
RMD Open; 2024 Jun; 10(2):. PubMed ID: 38871479
[TBL] [Abstract][Full Text] [Related]
11. Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases.
Mammoliti O; Martina S; Claes P; Coti G; Blanque R; Jagerschmidt C; Shoji K; Borgonovi M; De Vos S; Marsais F; Oste L; Quinton E; López-Ramos M; Amantini D; Brys R; Jimenez JM; Galien R; van der Plas S
J Med Chem; 2024 Jun; 67(11):8545-8568. PubMed ID: 38805213
[TBL] [Abstract][Full Text] [Related]
12. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.
Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W
Front Immunol; 2022; 13():884399. PubMed ID: 35693820
[TBL] [Abstract][Full Text] [Related]
13. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of tyrosine kinase 2 in autoimmunity.
Liang Y; Zhu Y; Xia Y; Peng H; Yang XK; Liu YY; Xu WD; Pan HF; Ye DQ
Expert Opin Ther Targets; 2014 May; 18(5):571-80. PubMed ID: 24654603
[TBL] [Abstract][Full Text] [Related]
15. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
Alunno A; Padjen I; Fanouriakis A; Boumpas DT
Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
[TBL] [Abstract][Full Text] [Related]
16. Potent and Selective Knockdown of Tyrosine Kinase 2 by Antisense Oligonucleotides.
Tran NV; Nguyen LTA; Lim KW; Phan AT
Immunohorizons; 2021 Feb; 5(2):70-80. PubMed ID: 33542028
[TBL] [Abstract][Full Text] [Related]
17. Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors.
Zhang K; Ye K; Tang H; Qi Z; Wang T; Mao J; Zhang X; Jiang S
J Med Chem; 2023 Apr; 66(7):4378-4416. PubMed ID: 36951608
[TBL] [Abstract][Full Text] [Related]
18. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).
He X; Chen X; Zhang H; Xie T; Ye XY
Expert Opin Ther Pat; 2019 Feb; 29(2):137-149. PubMed ID: 30621465
[TBL] [Abstract][Full Text] [Related]
19. English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis.
Saeki H; Mabuchi T; Asahina A; Abe M; Igarashi A; Imafuku S; Okubo Y; Komine M; Takahashi K; Torii H; Morita A; Yotsuyanagi H; Watanabe A; Ohtsuki M;
J Dermatol; 2023 May; 50(5):e138-e150. PubMed ID: 37132187
[TBL] [Abstract][Full Text] [Related]
20. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
Huang MY; Armstrong AW
Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):30-40. PubMed ID: 38031699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]